Daniela Berg
#125,797
Most Influential Person Now
Researcher
Daniela Berg's AcademicInfluence.com Rankings
Daniela Bergcomputer-science Degrees
Computer Science
#5272
World Rank
#5569
Historical Rank
Machine Learning
#1331
World Rank
#1352
Historical Rank
Artificial Intelligence
#1569
World Rank
#1599
Historical Rank
Database
#2429
World Rank
#2546
Historical Rank
Download Badge
Computer Science
Daniela Berg's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Daniela Berg Influential?
(Suggest an Edit or Addition)Daniela Berg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
- Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease (2009) (1770)
- The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
- Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. (2009) (965)
- MDS research criteria for prodromal Parkinson's disease (2015) (897)
- Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. (2005) (576)
- Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database (2012) (546)
- Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin (2007) (523)
- Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. (2013) (451)
- 14-3-3 proteins in the nervous system (2003) (426)
- iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis (2014) (417)
- Mutations in the gene encoding ɛ-sarcoglycan cause myoclonus–dystonia syndrome (2001) (397)
- Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. (2002) (388)
- Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
- A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
- EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
- Vulnerability of the nigrostriatal system as detected by transcranial ultrasound (1999) (326)
- Update of the MDS research criteria for prodromal Parkinson's disease (2019) (313)
- Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings (2001) (303)
- Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype (1999) (300)
- Genome-wide association study of intracranial aneurysm identifies three new risk loci (2010) (298)
- Progression of Parkinson's disease in the clinical phase: potential markers (2009) (294)
- A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease (2011) (278)
- Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
- Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. (2005) (271)
- SNCA variants are associated with increased risk for multiple system atrophy (2009) (263)
- Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain (2008) (261)
- Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. (2001) (253)
- Five‐year follow‐up study of hyperechogenicity of the substantia nigra in Parkinson's disease (2005) (245)
- Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. (2020) (241)
- Advances in markers of prodromal Parkinson disease (2016) (237)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- Transcranial brain parenchyma sonography in movement disorders: state of the art. (2007) (230)
- Brain iron pathways and their relevance to Parkinson's disease. (2001) (225)
- The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study (2008) (223)
- GBA-associated PD presents with nonmotor characteristics (2011) (220)
- Role of Iron in Neurodegenerative Disorders (2006) (217)
- Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration (2007) (213)
- Phosphorylated α-Synuclein in Parkinson’s Disease (2012) (203)
- Transcranial sonography in movement disorders (2008) (203)
- Multiple regions of α‐synuclein are associated with Parkinson's disease (2005) (195)
- GBA‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study (2015) (190)
- Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies (2014) (185)
- Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis (2011) (184)
- Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. (2009) (183)
- Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. (2004) (178)
- AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials (2011) (168)
- Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics (2009) (166)
- In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage (2006) (166)
- Iron accumulation in the substantia nigra in rats visualized by ultrasound. (1999) (165)
- Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study (2013) (163)
- Brain iron pathways and their relevance to Parkinson's disease (2001) (161)
- Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. (2011) (159)
- The Patients' Perception of Prodromal Symptoms Before the Initial Diagnosis of Parkinson's Disease (2011) (158)
- Relationship of substantia nigra echogenicity and motor function in elderly subjects (2001) (155)
- Iron metabolism in Parkinsonian syndromes (2006) (154)
- Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound (2005) (153)
- Validation of the MDS clinical diagnostic criteria for Parkinson's disease (2018) (153)
- S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway (2012) (151)
- Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study (2001) (144)
- Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities (2013) (144)
- Health-Related Quality of Life in patients with Parkinson's disease—A systematic review based on the ICF model (2016) (141)
- Redox imbalance (2004) (140)
- Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) (2004) (138)
- Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease (2008) (137)
- [11C]PIB binding in Parkinson's disease dementia (2008) (128)
- Multiregional brain iron deficiency in restless legs syndrome (2008) (124)
- Substantia nigra hypoechogenicity: Definition and findings in restless legs syndrome (2007) (124)
- Defining at‐risk populations for Parkinson's disease: Lessons from ongoing studies (2012) (124)
- Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease (2013) (119)
- The PRIPS study: screening battery for subjects at risk for Parkinson's disease (2013) (118)
- Arm swing as a potential new prodromal marker of Parkinson's disease (2016) (118)
- Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model (2007) (118)
- Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging (1999) (115)
- Lesion pattern in patients with multiple sclerosis and depression (2000) (112)
- Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease (2004) (111)
- Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry (2017) (110)
- Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy (2001) (107)
- Prodromal features for Parkinson's disease – baseline data from the TREND study (2014) (106)
- Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. (2013) (106)
- Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease (2003) (103)
- In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage (2005) (102)
- Gait analysis with wearables predicts conversion to Parkinson disease (2019) (101)
- Prodromal Parkinson disease subtypes — key to understanding heterogeneity (2021) (99)
- Loss of nocturnal blood pressure fall in various extrapyramidal syndromes (2009) (98)
- Prodromal Parkinson's Disease: The Decade Past, the Decade to Come (2019) (97)
- Phosphorylated alpha-Synuclein in Parkinson's Disease (2012) (96)
- Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
- Genetic analysis of immunomodulating factors in sporadic Parkinson's disease (2000) (95)
- Differentiation between intracerebral hemorrhage and ischemic stroke by transcranial color-coded duplex-sonography. (1998) (93)
- Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort (2017) (91)
- Biomarkers for the Early Detection of Parkinson’s and Alzheimer’s Disease (2008) (90)
- Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker (2009) (89)
- Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism (2020) (88)
- Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly – Baseline Results from the TREND Study (2011) (86)
- Impaired Trunk Stability in Individuals at High Risk for Parkinson's Disease (2012) (84)
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022) (84)
- Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease (2010) (83)
- Microglia activation is related to substantia nigra echogenicity (2010) (82)
- The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. (2000) (82)
- Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. (2016) (81)
- miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease (2018) (81)
- Alpha‐synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients (2005) (79)
- Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease (2017) (78)
- The basal ganglia in haemochromatosis (2000) (77)
- Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study (2013) (77)
- Functional relevance of ceruloplasmin mutations in Parkinson's Disease (2005) (76)
- Iron as a therapeutic target for Parkinson's disease (2018) (76)
- Cognitive changes in prodromal Parkinson's disease: A review (2017) (76)
- The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward (2017) (74)
- The new definition and diagnostic criteria of Parkinson's disease (2016) (74)
- Iron in neurodegenerative disorders (2002) (74)
- Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases (2016) (74)
- Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. (2001) (73)
- Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study (2016) (73)
- L‐dopa increases α‐synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro (2015) (73)
- The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect (2012) (72)
- α-Synuclein in Parkinson’s disease: causal or bystander? (2019) (71)
- Genome-wide association study in essential tremor identifies three new loci (2016) (70)
- Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics (2011) (70)
- Clinical and brain imaging characteristics in leucine‐rich repeat kinase 2–associated PD and asymptomatic mutation carriers (2011) (69)
- Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease (2004) (69)
- ATP13A2 variants in early‐onset Parkinson's disease patients and controls (2009) (68)
- Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson’s Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back (2017) (67)
- Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts (2017) (66)
- Predictive value of transcranial sonography in the diagnosis of Parkinson's disease (2006) (65)
- Quality of life in patients with blepharospasm (2001) (65)
- Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease (2007) (64)
- Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis (2009) (64)
- 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. (2002) (62)
- Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease (2010) (61)
- Assessment of idiopathic rapid‐eye‐movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP‐CIT‐SPECT (2008) (59)
- Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease (2018) (59)
- A critique of the second consensus criteria for multiple system atrophy (2019) (59)
- In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin (2016) (58)
- Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial (2019) (58)
- Common variants of LRRK2 are not associated with sporadic Parkinson's disease (2005) (57)
- Reduction of dyskinesia and induction of akinesia induced by morphine in two Parkinsonian patients with severe sciatica (1999) (56)
- Specification of 14‐3‐3 proteins in Lewy bodies (2003) (56)
- Psychopathological Symptoms of Depression in Parkinson’s Disease Compared to Major Depression (2003) (55)
- Genetics and iron in the systems biology of Parkinson’s disease and some related disorders (2013) (54)
- Sonographic abnormalities of brainstem structures in restless legs syndrome. (2008) (54)
- Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. (2011) (54)
- Case report Man‐in‐the‐barrel syndrome caused by cervical spinal cord infarction (1998) (53)
- Characterizing POLG Ataxia: Clinics, Electrophysiology and Imaging (2012) (53)
- NOVEL ATP1A3 MUTATION IN A SPORADIC RDP PATIENT WITH MINIMAL BENEFIT FROM DEEP BRAIN STIMULATION (2008) (52)
- Inflammatory profile in LRRK2-associated prodromal and clinical PD (2016) (52)
- Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson’s Disease: Implications for Idiopathic and Monogenetic Forms (2007) (52)
- Inherited myoclonus‐dystonia syndrome: Narrowing the 7q21‐q31 locus in German families (2001) (52)
- Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration—[18F]FDG‐PET (2009) (51)
- Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET (2009) (51)
- Validating Alzheimer's disease micro RNAs using next-generation sequencing (2016) (50)
- Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly (2010) (50)
- Validation of conversion between mini–mental state examination and montreal cognitive assessment (2016) (50)
- Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease (2006) (50)
- Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population (2011) (50)
- Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson’s disease (2011) (49)
- The proteasomal subunit S6 ATPase is a novel synphilin‐1 interacting protein—implications for Parkinson's disease (2007) (49)
- The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations (2005) (49)
- Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra (2003) (49)
- Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease (2020) (49)
- Perspectives of B-Mode Transcranial Ultrasound (2002) (48)
- Machine Learning to Detect Alzheimer’s Disease from Circulating Non-coding RNAs (2019) (48)
- Application of transcranial sonography in extrapyramidal disorders: updated recommendations. (2006) (48)
- Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease (2014) (47)
- Alterations in Blood Monocyte Functions in Parkinson's Disease (2019) (47)
- Illicit Stimulant Use Is Associated with Abnormal Substantia Nigra Morphology in Humans (2013) (47)
- Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases (2011) (46)
- Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients (2010) (46)
- Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes (2008) (46)
- Transcranial sonography in spinocerebellar ataxia type 3. (2004) (46)
- Cross-sectional study discloses a positive family history for Parkinson’s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity (2007) (45)
- Transcranial sonography findings related to non-motor features of Parkinson's disease (2010) (45)
- Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
- Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition (2018) (45)
- Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. (2011) (45)
- Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance (2020) (45)
- Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra (2006) (44)
- Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools (2013) (44)
- Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy (2009) (44)
- Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? (2018) (44)
- Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson’s disease (2015) (44)
- Vascular Risk Factors and Cognition in Parkinson's Disease. (2016) (43)
- Influence of Different Cut-Off Values on the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease (2011) (42)
- SNCA: Major genetic modifier of age at onset of Parkinson's disease (2013) (42)
- Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s Disease (2017) (41)
- Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK) (2011) (41)
- Risk factors and prodromal markers and the development of Parkinson’s disease (2013) (41)
- Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes (2010) (41)
- Friedreich Ataxia: Dysarthria Profile and Clinical Data (2013) (41)
- Screening for prodromal Parkinson's disease in the general community: a sleep-based approach. (2016) (41)
- Valsalva manoeuvre in patients with different Parkinsonian disorders (2009) (40)
- Transcranial sonography of the brain parenchyma: comparison of B-mode imaging and tissue harmonic imaging. (2000) (40)
- Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis (2010) (40)
- Inflammatory profile discriminates clinical subtypes in LRRK2‐associated Parkinson's disease (2017) (40)
- Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature (2016) (39)
- Transcranial ultrasound as a risk marker for Parkinson's disease (2009) (39)
- Associations between Early Markers of Parkinson's Disease and Sarcopenia (2017) (38)
- Consensus for the measurement of the camptocormia angle in the standing patient. (2018) (38)
- Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. (2006) (38)
- Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring (2018) (38)
- The significance of GBA for Parkinson’s disease (2014) (36)
- Autonomic dysfunction in different subtypes of multiple system atrophy (2008) (36)
- Analysis of ACTA2 in European Moyamoya disease patients. (2011) (36)
- Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway. (2011) (36)
- Recent advances in understanding and managing sepsis (2018) (36)
- Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation (2008) (35)
- Cerebral activation pattern in primary writing tremor (2000) (35)
- No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort (2011) (35)
- State-dependent altered connectivity in late-life depression: a functional near-infrared spectroscopy study (2016) (34)
- Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. (2009) (34)
- Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls (2014) (34)
- Alpha Synuclein Connects the Gut-Brain Axis in Parkinson’s Disease Patients – A View on Clinical Aspects, Cellular Pathology and Analytical Methodology (2020) (34)
- Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria (2019) (34)
- Effect of Fear of Falling on Turning Performance in Parkinson’s Disease in the Lab and at Home (2018) (34)
- The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. (2010) (34)
- Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy‐parkinsonism (2012) (34)
- Mild Parkinsonian Signs in the Elderly – Is There an Association with PD? Crossectional Findings in 992 Individuals (2014) (34)
- Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls (2014) (34)
- Mutation analysis of the neurofilament M gene in Parkinson's disease (2003) (34)
- Improvement of balance after audio-biofeedback (2010) (33)
- The spectrum of progressive multifocal leukoencephalopathy: a practical approach (2019) (33)
- Sustained dopaminergic response of parkinsonism and depression in POLG‐associated parkinsonism (2010) (32)
- The New Diagnostic Criteria for Parkinson's Disease. (2017) (32)
- Autonomic dysfunction in patients with progressive supranuclear palsy (2008) (32)
- Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease (2016) (32)
- The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. (2017) (32)
- Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson’s disease (2011) (32)
- Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. (2007) (31)
- The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients. (2011) (31)
- Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies (2012) (31)
- Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations (2021) (31)
- Decreased α-Synuclein Serum Levels in Patients with Lewy Body Dementia Compared to Alzheimer’s Disease Patients and Control Subjects (2011) (31)
- Less Is More – Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings (2019) (31)
- Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies and Lessons Learned (2016) (31)
- Milestones in magnetic resonance imaging and transcranial sonography of movement disorders (2011) (31)
- The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA (2021) (30)
- Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: The Progression Markers in the Premotor Phase Study (2013) (30)
- Progress of Pharmacological Approaches in Parkinson's Disease (2019) (30)
- Substantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: yes (2011) (30)
- Is pre-motor diagnosis possible? The European experience. (2012) (30)
- No association of GBA mutations and multiple system atrophy (2013) (29)
- Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly (2018) (29)
- Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles (2020) (29)
- Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population (2008) (29)
- Progressive Gait Deficits in Parkinson’s Disease: A Wearable-Based Biannual 5-Year Prospective Study (2019) (29)
- Transcranial sonography in the early and differential diagnosis of Parkinson's disease. (2006) (28)
- Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease (2020) (28)
- Screening for mutations of the IRP2 gene in Parkinson’s disease patients with hyperechogenicity of the substantia nigra (2004) (28)
- Clinical and dual‐tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy (2010) (27)
- TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. (2015) (27)
- A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia (2016) (27)
- Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging (2013) (27)
- An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial (2019) (27)
- Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson’s Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back (2017) (27)
- Common diseases alter the physiological age-related blood microRNA profile (2020) (27)
- Does ultrasound disclose a vulnerability factor for Parkinson's disease? (2003) (26)
- Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System (2019) (26)
- Evidence for disturbances of copper metabolism in dystonia (2001) (26)
- Cerebrospinal fluid biomarkers and clinical features in leucine‐rich repeat kinase 2 (LRRK2) mutation carriers (2016) (26)
- Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes (2021) (26)
- Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia (2012) (26)
- Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease? (2019) (25)
- Age‐ and sex‐related heterogeneity in prodromal Parkinson's disease (2018) (25)
- Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease. (2010) (25)
- Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. (2017) (25)
- Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson’s disease diagnosis (2018) (25)
- Developments in the Role of Transcranial Sonography for the Differential Diagnosis of Parkinsonism (2015) (25)
- Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans (2011) (25)
- Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease. (2004) (25)
- Relation of risk factors and putative premotor markers for Parkinson’s disease (2011) (25)
- Design of the Park-in-Shape study: a phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson’s disease (2015) (25)
- Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson’s Disease during Single and Dual Tasking (2016) (24)
- Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors (2016) (24)
- Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD (2015) (24)
- Digitomotography in Parkinson’s Disease: A Cross-Sectional and Longitudinal Study (2015) (24)
- In vivo comparison of Richardson’s syndrome and progressive supranuclear palsy-parkinsonism (2011) (24)
- Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes (2007) (24)
- Autonomic dysfunction in subjects at high risk for Parkinson’s disease (2015) (23)
- Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People (2017) (23)
- Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency (2015) (23)
- GBA-associated PD (2012) (23)
- GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson’s Disease and Lewy Body Dementia (2016) (23)
- Transcranial Sonography Reveals Cerebellar, Nigral, and Forebrain Abnormalities in Friedreich’s Ataxia (2011) (23)
- The role of α-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies (2005) (22)
- Validation of a Lower Back “Wearable”-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment (2018) (22)
- Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. (2013) (22)
- Instrumented Functional Reach Test Differentiates Individuals at High Risk for Parkinson’s Disease from Controls (2014) (22)
- Reduction of Menkes mRNA and copper in leukocytes of patients with primary adult‐onset dystonia (2001) (22)
- How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study. (2013) (22)
- Role of transcranial ultrasound in the diagnosis of movement disorders. (2010) (22)
- Nutrition and the risk for Parkinson’s disease: review of the literature (2008) (22)
- Gut microbiome signatures of risk and prodromal markers of Parkinson's disease. (2021) (21)
- Retinal nerve fiber layer loss in multiple system atrophy (2011) (21)
- Morphine in tardive and idiopathic dystonia (2001) (21)
- Insulin sensitivity predicts cognitive decline in individuals with prediabetes (2020) (21)
- Ultrasound in the (premotor) diagnosis of Parkinson's disease. (2007) (21)
- LINGO1 is not associated with Parkinson's disease in German patients (2010) (21)
- Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. (2010) (21)
- Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. (2011) (21)
- Cerebrospinal fluid fatty acids in glucocerebrosidase‐associated Parkinson's disease (2012) (21)
- Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles (2017) (21)
- EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts (2014) (21)
- Clinical, genetic, and brain sonographic features related to Parkinson’s disease in Gaucher disease (2013) (20)
- Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications (2020) (20)
- Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease (2019) (20)
- Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson’s disease patients (2009) (20)
- High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia (2014) (20)
- Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. (2021) (20)
- Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration? (2015) (19)
- Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. (2015) (19)
- Orthostatic hypotension as a risk factor for longitudinal deterioration of cognitive function in the elderly (2020) (19)
- Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson’s disease (2012) (19)
- Postnatal decrease in substantia nigra echogenicity (2004) (19)
- Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. (2016) (18)
- Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. (2015) (18)
- Transcranial sonography in the premotor diagnosis of Parkinson's disease. (2010) (18)
- Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease (2020) (18)
- Phenylalanine Effects on Brain Function in Adult Phenylketonuria (2020) (18)
- Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha‐synuclein profile (2019) (18)
- Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson’s disease patients (2009) (18)
- Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls (2019) (18)
- Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in “cognitive status” converters? (2019) (18)
- Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study (2015) (18)
- Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. (2018) (18)
- Potential Markers of Progression in Idiopathic Parkinson’s Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study (2019) (18)
- A Neurodegenerative Vascular Burden Index and the Impact on Cognition (2014) (18)
- Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays (2014) (17)
- Biomarkers of Parkinson’s disease: 20 years later (2019) (17)
- Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy (2012) (17)
- Role of ANO3 mutations in dystonia: A large-scale mutational screening study. (2019) (17)
- Split-belt treadmill walking in patients with Parkinson's disease: A systematic review. (2019) (17)
- Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor (2016) (16)
- Life-threatening DBS withdrawal syndrome in Parkinson's disease can be treated with early reimplantation. (2018) (16)
- Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. (2000) (16)
- Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs (2016) (16)
- Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease (2020) (16)
- Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies (2016) (16)
- Patients' views on the ethical challenges of early Parkinson disease detection (2020) (16)
- The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. (2005) (15)
- Clock Test Deficits Related to the Global Cognitive State in Alzheimer’s and Parkinson’s Disease (2012) (15)
- Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
- Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment – the ComOn-study (2020) (15)
- Early diagnosis of Parkinson's disease. (2010) (15)
- Restless Legs and Substantia Nigra Hypoechogenicity are Common Features in Friedreich’s Ataxia (2011) (15)
- Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment (2016) (15)
- Analysis of TGFB1 in European and Japanese Moyamoya disease patients. (2012) (15)
- Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
- Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors (2007) (14)
- Structural brain signature of cognitive decline in Parkinson’s disease: DTI-based evidence from the LANDSCAPE study (2019) (14)
- Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse (2002) (14)
- Poor effect of guideline based treatment of restless legs syndrome in clinical practice (2010) (14)
- Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity (2021) (14)
- Prodromal PD: A new nosological entity. (2020) (14)
- Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus (2016) (14)
- Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome (2009) (14)
- No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease in nine ADHD candidate SNPs (2017) (13)
- Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson’s disease (2018) (13)
- No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases (2009) (13)
- Structural Ultrasound of the Medial Temporal Lobe in Alzheimer’s Disease (2016) (13)
- Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound. (2010) (13)
- Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease (2018) (13)
- Patient's perception: shorter and more severe prodromal phase in GBA‐associated PD (2018) (13)
- Cognitive response control in writer’s cramp (2001) (13)
- Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
- A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease (2009) (13)
- Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus. (2016) (13)
- Differences in Substantia nigra Echogenicity of Nosological Subtypes within the Schizophrenic Spectrum (2001) (13)
- Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults (2017) (13)
- Cognitive Profiles in Parkinson's Disease and Their Relation to Dementia: A Data-Driven Approach (2012) (12)
- Substantia Nigra Hyperechogenicity (2016) (12)
- Substantia nigra echomorphology and motor cortex excitability (2010) (12)
- Screening for mutations in synaptotagmin XI in Parkinson's disease. (2004) (12)
- Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia (2013) (12)
- Arm swing asymmetry in overground walking (2018) (12)
- Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults (2016) (12)
- The Multiple Object Test as a Performance Based Tool to Assess Cognitive Driven Activity of Daily Living Function in Parkinson's Disease. (2016) (11)
- Place Value of Transcranial Sonography in Early Diagnosis of Parkinson’s Disease (2010) (11)
- Morphine in tardive and idiopathic dystonia (short communication). (2001) (11)
- Progression of prodromal motor and non‐motor symptoms in the premotor phase study – 2‐year follow‐up data (2017) (11)
- Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson's disease and non-PD controls (2017) (11)
- The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study (2018) (11)
- Transcranial sonography in psychiatry as a potential tool in diagnosis and research (2018) (10)
- From Prodromal to Overt Parkinson’s Disease: Towards a New Definition in the Year 2040 (2018) (10)
- Genetic causes of Parkinson's disease: extending the pathway. (2006) (10)
- Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1–42 profiles in a prospective longitudinal study (2018) (10)
- Trial of Deferiprone in Parkinson's Disease. (2022) (10)
- Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease (2018) (10)
- Evaluation of the ventricular system in children using transcranial ultrasound: reference values for routine diagnostics. (2004) (10)
- Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD) (2018) (10)
- No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors (2019) (10)
- Comprehensive association analysis of the NOS2A gene with Parkinson disease (2006) (10)
- Association between cognitive impairment and urinary dysfunction in Parkinson’s disease (2017) (10)
- Neurogeriatrics—a vision for improved care and research for geriatric patients with predominating neurological disabilities (2020) (10)
- Effects of exergaming on hippocampal volume and brain‐derived neurotrophic factor levels in Parkinson’s disease (2021) (10)
- Stepwise isolation of human peripheral erythrocytes, T lymphocytes, and monocytes for blood cell proteomics (2012) (10)
- Third ventricular width assessed by transcranial ultrasound correlates with cognitive performance in Parkinson's disease. (2019) (10)
- The cold hand sign in multiple system atrophy: skin perfusion revisited (2010) (10)
- Progression markers of motor deficits in Parkinson's disease: A biannual 4‐year prospective study (2017) (10)
- Multiomics Analyses Identify Genes and Pathways Relevant to Essential Tremor (2020) (9)
- Risk Disclosure in Prodromal Parkinson's Disease (2021) (9)
- Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases (2011) (9)
- The Multiple Object Test as a performance-based tool to assess the decline of ADL function in Parkinson’s disease (2018) (9)
- Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study (2018) (9)
- Erratum: Structural Ultrasound of the Medial Temporal Lobe in Alzheimer’s Disease (2016) (9)
- GBA‐associated parkinsonism and dementia: beyond α‐synucleinopathies? (2016) (9)
- Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson’s Disease (2021) (9)
- No association between NOD2 variants and Parkinson's disease (2012) (9)
- Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls. (2019) (9)
- In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody (2014) (8)
- Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer’s disease with FDG-PET (2019) (8)
- Functional movement disorders in neurogeriatric inpatients (2019) (8)
- A case of CLIPPERS syndrome responsive to tocilizumab (2019) (8)
- Transcranial sonographic findings may predict prognosis of gastroprokinetic drug-induced parkinsonism. (2018) (8)
- The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders (2015) (8)
- Maximizing the Potential of Longitudinal Cohorts for Research in Neurodegenerative Diseases: A Community Perspective (2017) (8)
- Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes (2017) (8)
- Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants (2014) (8)
- Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia (2020) (8)
- Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson’s Disease Rating Scale in the elderly population (2015) (8)
- Using genome-Wwide complex trait analysis to quantify 'missing heritability' in Parkinson's disease (2012) (8)
- Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression. (2012) (8)
- The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease (2021) (8)
- Parenchymal imaging in movement disorders. (2015) (7)
- Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
- Step Length Is a Promising Progression Marker in Parkinson’s Disease (2021) (7)
- Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation (2020) (7)
- Gut microbiome signatures of risk and prodromal markers of Parkinson’s disease (2019) (7)
- How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders? (2020) (7)
- Transcranial B-Mode Sonography in Movement Disorders. (2018) (7)
- Can we define “pre‐motor” Parkinson's disease? (2012) (7)
- Dual-Task Performance in GBA Parkinson's Disease (2017) (7)
- SNPs in A&bgr; clearance proteins: Lower CSF A&bgr;1-42 levels and earlier onset of dementia in PD (2017) (7)
- Parkinson disease in 2017: Changing views after 200 years of Parkinson disease (2018) (7)
- Botulinum toxin and occupational therapy in the treatment of writer's cramp (1999) (6)
- Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany (2010) (6)
- Motor cortical excitability and paired-associative stimulation-induced plasticity in amnestic mild cognitive impairment and Alzheimer’s disease (2021) (6)
- Enhancement of Executive Functions but Not Memory by Multidomain Group Cognitive Training in Patients with Parkinson's Disease and Mild Cognitive Impairment: A Multicenter Randomized Controlled Trial (2020) (6)
- Parkinson’s disease with and without preceding essential tremor-similar phenotypes: a pilot study (2014) (6)
- Parkinson disease genetics: too early to predict progression? (2019) (6)
- Quantitative motor assessment of dyskinesias in Parkinson’s disease (2015) (6)
- Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease (2008) (6)
- Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson’s Disease (2016) (6)
- No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease (2013) (5)
- Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease (2021) (5)
- The effect of age and gender on anti‐saccade performance: Results from a large cohort of healthy aging individuals (2020) (5)
- Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. (2018) (5)
- Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients. (2020) (5)
- Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson’s disease patients (2018) (5)
- Transcranial Sonography Findings in Alzheimer’s Disease: A New Imaging Biomarker (2020) (5)
- Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future (2011) (5)
- Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson’s Disease (2020) (5)
- Therapeutic strategies for Parkinson's disease based on data derived from genetic research (2003) (5)
- Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson’s Disease (2021) (5)
- Genome-wide association studies of LRRK2 modifiers of Parkinson's disease (2020) (4)
- Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. (2022) (4)
- Biomarkers of Alzheimer's and Parkinson's Disease (2010) (4)
- Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients. (2020) (4)
- Memory enhancement by multidomain group cognitive training in patients with Parkinson’s disease and mild cognitive impairment: long-term effects of a multicenter randomized controlled trial (2021) (4)
- [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]. (2008) (4)
- A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk (2022) (4)
- Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus (2022) (4)
- SNPs in Aβ clearance proteins (2017) (4)
- Post-Cueing Deficits with Maintained Cueing Benefits in Patients with Parkinson’s Disease Dementia (2014) (4)
- Prodromal features of Parkinson's disease: Self‐reported symptoms versus clinically assessed signs (2018) (4)
- The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri (2010) (4)
- The Hospital-Wide Implementation of Shared Decision-Making. (2021) (4)
- Spin turns in advanced Parkinson's disease: A new clinical gait sign? (2019) (3)
- Private variants in PRKN are associated with late-onset Parkinson's disease. (2020) (3)
- Cholinergic Pathway SNPs and Postural Control in 477 Older Adults (2018) (3)
- Biomarkers for PD (2013) (3)
- Walking parameters of older adults from a lower back inertial measurement unit, a 6-year longitudinal observational study (2022) (3)
- Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). (2018) (3)
- Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. (2020) (3)
- 3rd International Congress on Neurology and Epidemiology. Abu Dhabi, UAE, November 21–23, 2013: Abstracts (2013) (3)
- Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. (2020) (3)
- Evaluating a Patient with Transcranial Sonography to Look for Echogenicity (2017) (3)
- Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's disease–a fNIRS study (2021) (3)
- Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease (2009) (3)
- White Matter Hyperintensities Are Associated With Severity of Essential Tremor in the Elderly (2021) (3)
- SNPs in A beta clearance proteins Lower CSF A beta(1-42) levels and earlier onset of dementia in PD (2017) (3)
- Chapter 7 – Redox Imbalance: In the Triad of Genetic Disturbances and Mitochondrial Dysfunction in Parkinson's Disease (2007) (3)
- Measurement of the adult human midbrain with transcranial ultrasound (2021) (3)
- “Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease (2016) (3)
- Hand function is impaired in healthy older adults at risk of Parkinson’s disease (2014) (3)
- Comparing the Two Prodromal Parkinson's Disease Research Criteria—Lessons for Future Studies (2021) (2)
- A time-efficient screening tool for activities of daily living functions in Parkinson’s disease dementia (2020) (2)
- Increased Intake of Fast-Acting Carbohydrates in Patients with Parkinson’s Disease (2021) (2)
- Candidate variants in TUB are associated with familial tremor (2020) (2)
- Algorithm for Turning Detection and Analysis Validated under HomeLike Conditions in Patients with Parkinson ? s Disease and Older Adults using a 6 Degree (2017) (2)
- Movement disorders: discoveries in pathophysiology and therapy (2015) (2)
- Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease (2022) (2)
- Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
- Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease (2009) (2)
- Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach (2016) (2)
- Bilateral vertebral artery dissection in the setting of ADEM (2016) (2)
- Self estimated quality of life in monogenetic Parkinson's disease (2011) (2)
- Substantia nigra hyperechogenicity in healthy controls: a [18Fluoro] Dopa-PET follow-up study (2013) (2)
- Design of the Park-in-Shape study (2015) (2)
- Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving (2022) (2)
- Improving statistical analysis in brain imaging: an alternative way to use principal component analysis (2018) (1)
- V41. Static sway patterns of individuals with increased risk for, and converters to Parkinson’s disease. Analysis of 700 participants of the TREND-study (2015) (1)
- Increased functional connectivity in a population at risk of developing Parkinson's disease. (2021) (1)
- Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments (2021) (1)
- POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study (2012) (1)
- Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson’s Disease (2020) (1)
- P103 AFQ056 treatment of levodopa-induced dyskinesias: Results of two randomized controlled trials (2011) (1)
- [Transcraniel ultrasound in the differential diagnosis of Parkinson's disease]. (2010) (1)
- Update on Parkinson's Disease Genetics (2007) (1)
- Substantia Nigra Hyperechogenicity for the Early Detection of ParkinsonâÂÂsDisease (2017) (1)
- Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life (2021) (1)
- Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners? (2020) (1)
- Characterizing mixed location hemorrhages/microbleeds with CSF markers. (2023) (1)
- A blood marker for Parkinson’s Disease: Neuronal exosome-derived α-synuclein (2021) (1)
- Conditional control of human wildtype and mutated [A30P] alpha-synuclein in a mouse model of Parkinson's disease (2005) (1)
- 5th International Conference on Neurology and Epidemiology. Gold Coast, Australia, November 18-20, 2015: Abstracts (2015) (1)
- Dopaminergic Therapies for Non-motor Symptoms in Parkinson's (2017) (1)
- A Klinefelter patient with an additional mitochondrial mutation: Implications for genotype-driven treatment and mitochondrial mutational load in different tissues and family members. (2018) (1)
- Reply to “Quantitative Motor Functioning in Prodromal Parkinson Disease” (2019) (1)
- Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease (2008) (1)
- P171. The relationship between quantitative parameters of the Timed-up-and-Go phases, and health-related quality of life in Parkinson’s disease (2015) (1)
- Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models? (2019) (0)
- P167. Dual tasking deficits in motor tasks predict falls in Parkinson’s disease (2015) (0)
- Transcranial sonography in movement disorders. Conclusions. (2010) (0)
- MS and related disorders: looking for markers of phenotypes (2015) (0)
- Contents Vol. 37, 2011 (2011) (0)
- P178. The effect of cognitively challenging tasks on walking in Parkinson’s Patients (2015) (0)
- Q&A With Drs. Daniela Berg and Ronald Postuma (2016) (0)
- Transcranial Sonography in Parkinsonian Syndromes (2011) (0)
- Gait decline while dual-tasking is an early sign of white matter deterioration in middle-aged and older adults (2022) (0)
- Complications following REM sleep behavior disorder (2021) (0)
- Questionnaires as screening tools to identify persons with hearing deficiencies (2018) (0)
- In reply. (2013) (0)
- Friedreich Ataxia: Dysarthria Profile and Clinical Data (2013) (0)
- Preface. Summary of content--TCS in the diagnosis of movement disorders. (2010) (0)
- Neuroimaging of Sleep and Sleep Disorders: Fundamentals of transcranial B-mode sonography (2013) (0)
- MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON’S DISEASE (2019) (0)
- P126 LINGO1 is not associated with Parkinson’s disease in German patients (2011) (0)
- Poster Session 3 Tuesday , June 25 between 10 : 00 and 12 : 00 L-Falls and falls prevention ; Aging P 3L-152 Analysis Of 857 Cases With In-Hospital Falls (2013) (0)
- IV.P4 Treatment with cholinesterase inhibitors in supranuclear palsy: a preliminary case-series (2006) (0)
- P3-280 Higher peripheral regulatory T cell activity in parkinson but not Alzheimer’s disease (2006) (0)
- P116 TAUROS: A clinical trial on Progressive Supranuclear Palsy with the GSK-3 inhibitor Tideglusib (Zentylor®) (2011) (0)
- MDS Research Criteria for Prodromal Pakrinson's Disease (I1.011) (2016) (0)
- [New therapy approaches for Parkinson's disease]. (2017) (0)
- Differences between patients with Parkinson ' s disease and healthy controls detected by high spatial resolution 3 D-MRSI at 3 T (2009) (0)
- FV4 Brain atrophy distribution and rate of change in patients with advanced Parkinsons disease and cognitive impairment (2020) (0)
- Conditional control of human wild-type and Parkinson's disease-associated mutant alpha-synuclein in transgenic mouse brain (2004) (0)
- Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease (2022) (0)
- α-synuclein seed amplification and its uses in Parkinson's disease (2023) (0)
- P109 Long-term follow-up of deep brain stimulation in Parkinson’s disease due to heterozygous mutations in the glucocerebrosidase gen (2011) (0)
- Hyperechogenicity of substantia nigra in Parkinson's disease – Searching for genetic predictors (2008) (0)
- FV 4 Electroencephalographic Activity as a potential prodromal marker for Parkinson’s disease (2019) (0)
- 3.062 ATAXIN-2 INTERMEDIATE POLYGLUTAMINE EXPANSIONS CONTRIBUTE TO RISK OF ALS AND OF EARLY ONSET HEREDITARY PD (2012) (0)
- Contents Vol. 41, 2013 (2013) (0)
- F-18-FDG PET in Richardson syndrome and PSP-P, two variants of supranuclear palsy (2011) (0)
- Reply (2003) (0)
- Publisher Correction: Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes (2022) (0)
- Characterizing POLG-Ataxia: Clinics, Electrophysiology, and Imaging (IN7-1.001) (2012) (0)
- II.P16 Osteopontin is elevated in Parkinson's Disease (PD) and PD with dementia (2006) (0)
- GENETICS OF NERVOUS SYSTEM DISEASES (0)
- Silent Saliva Aspiration in Parkinson ’ s Disease (2011) (0)
- Cognition as a key factor of bladder problems in Parkinson's disease (2017) (0)
- Affection of basal ganglia in spinocerebellar ataxia type 3- a transcrainal sonography study (2005) (0)
- Thyroid [123I]MIBG uptake in Parkinson's disease and diabetes mellitus. (2023) (0)
- Transcranial sonography in dystonia (2005) (0)
- Bayesian network modeling of risk and prodromal markers of Parkinson’s disease (2022) (0)
- FV 37 Cortical and subcortical volumetry in patients with Parkinsons disease and cognitive impairment (2019) (0)
- Featured Article Validating Alzheimer's disease micro RNAs using next-generation sequencing (2016) (0)
- Transcranial Ultrasound in Parkinson’s Disease (2012) (0)
- Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions (2020) (0)
- FV 36 Cognitive deficits and microstructural correlates in Parkinsons disease: DTI data from the LANDSCAPE study (2019) (0)
- O.043 Use of sonography in PD and related disorders – applications and perspectives (2009) (0)
- Author response for "The effect of age and gender on anti‐saccade performance: Results from a large cohort of healthy ageing individuals" (2020) (0)
- Novel ATP1A3 mutation in a sporadic RDP patient with partial benefit from deep brain stimulation (2007) (0)
- Longitudinal dynamics of depression in risk groups of older individuals during the COVID-19 pandemic (2023) (0)
- High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. (2008) (0)
- Inflammatory profile in LRRK2-associated prodromal and clinical PD (2016) (0)
- The deleterious effects of High Mobility Group Box 1 in the MPTP model and Parkinson's disease can be attenuated by glycyrrhizin (2014) (0)
- [18F]FDG-PET for diagnosis of dementia in Parkinson's disease (2008) (0)
- Effect of Lower Limb vs. Abdominal Compression on Mobility in Orthostatic Hypotension: A Single-Blinded, Randomized, Controlled, Cross-Over Pilot Study in Parkinson's Disease. (2022) (0)
- Characterisation of a conditional mouse-model of Parkinson's disease (2006) (0)
- WHO WILL DROP OUT NEXT? CHARACTERIZATION OF DROPOUTS IN A LARGE LONGITUDINAL STUDY (2017) (0)
- Technical Advance High-Throughput Homogeneous Mass Cleave Assay Technology for the Diagnosis of Autosomal Recessive Parkinson's Disease (2008) (0)
- A novel P159L mutation in the Parkin gene related to autosomal dominantly inherited late onset parkinsonism and protein aggregation (2004) (0)
- Contents Vol. 45, 2015 (2015) (0)
- Neurodegenerative Diseases: Pathophysiology: biochemistry of Parkinson's disease (2005) (0)
- 'Atypical' Parkinson's disease - sporadic. (2019) (0)
- Research report 1 protein is a component of Lewy bodies in Parkinson's disease—Mutation analysis and association studies of 14-3-3 eta (2002) (0)
- Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity (2021) (0)
- 250 CLINICAL ASPECTS AND DUAL-TASKING DISTINGUISH HIGH-FREQUENT FROM LOW-FREQUENT FALLERS IN PROGRESSIVE SUPRANUCLEAR PALSY (2010) (0)
- Machine learning-based personalized composite score dissects risk and protective factors for cognitive and motor function in elderly (2022) (0)
- Higher Frequencies of T-Cells Expressing NK-Cell Markers and Chemokine Receptors in Parkinson’s Disease (2022) (0)
- CAN DUAL TASK PARADIGMS CONTRIBUTE TO THE DIFFERENTIAL DIAGNOSIS BETWEEN DEPRESSION AND DEMENTIA/MCI? (2014) (0)
- Redefinition of Parkinson’s Disease (2017) (0)
- BERG, Daniela: Kiel/Germany (2019) (0)
- Transcranial Ultrasonography in Movement Disorders (2013) (0)
- ‘Cycling’ with long‐acting dopamine agonists for augmentation in restless legs syndrome (2016) (0)
- Comprehensive Implementation of Shared Decision Making in a Neuromedical Center Using the SHARE TO CARE Program (2023) (0)
- Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes (2022) (0)
- Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs (2016) (0)
- Heart rate variability and sympathetic skin response in Parkinson's disease: Baseline assessment of the MODEP study (2013) (0)
- Characterizing POLG Ataxia: Clinics, Electrophysiology and Imaging (2012) (0)
- P176. Quantitative analysis of anticipatory postural adjustment in patients with Parkinson’s disease (2015) (0)
- P40. Quantitative gait parameter changes under challenging single and dual tasking conditions are associated with Trail Making Test performance: Cross-sectional analysis in 661 elderly (2015) (0)
- Movement Disorders: More than just Parkinson’s disease (2017) (0)
- Cerebrotendinous xanthomatosis (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Daniela Berg?
Daniela Berg is affiliated with the following schools:
